The current study assessed renal function based on medical records in adult hematopoietic stem cell transplant (HSCT) recipients with proven or probable invasive fungal infection (IFI) transplanted between 1995 and 2000. We confirm that amphotericin B deoxycholate (AmB-d) is nephrotoxic in a large percentage of HSCT recipients. Due to nephrotoxicity, defined as serum creatinine (SCr) 42.5 mg/dl or a 100% increase in SCr from baseline, 88% of patients treated with AmB-d were switched to a lipid formulation of amphotericin B (LFAB). In total, 53% of patients initiated on AmB-d were switched within the first week of therapy. Significantly more patients (70.6%) treated with AmB-d experienced a 100% increase in SCr from baseline compared to patients treated with either AmBisome (44.4%) or Abelcet (41.2%). A Cox Proportional Hazards Model revealed that, compared to patients initiated on AmBisome or Abelcet, the risk of nephrotoxicity (RR ¼ 1.5 vs AmBisome; RR ¼ 1.7 vs Abelcet), dialysis (RR ¼ 2.4 vs AmBisome; RR ¼ 1.4 vs Abelcet), and death (RR ¼ 2.0 vs AmBisome; RR ¼ 1.1 vs Abelcet) were all increased for patients initiated on AmB-d. Study results suggest that renal function improves and mortality declines when an LFAB is given to HSCT patients as initial therapy rather than as second-line therapy, the current practice.
Summary:
The current study assessed renal function based on medical records in adult hematopoietic stem cell transplant (HSCT) recipients with proven or probable invasive fungal infection (IFI) transplanted between 1995 and 2000. We confirm that amphotericin B deoxycholate (AmB-d) is nephrotoxic in a large percentage of HSCT recipients. Due to nephrotoxicity, defined as serum creatinine (SCr) 42.5 mg/dl or a 100% increase in SCr from baseline, 88% of patients treated with AmB-d were switched to a lipid formulation of amphotericin B (LFAB). In total, 53% of patients initiated on AmB-d were switched within the first week of therapy. Significantly more patients (70.6%) treated with AmB-d experienced a 100% increase in SCr from baseline compared to patients treated with either AmBisome (44.4%) or Abelcet (41.2%). A Cox Proportional Hazards Model revealed that, compared to patients initiated on AmBisome or Abelcet, the risk of nephrotoxicity (RR ¼ 1.5 vs AmBisome; RR ¼ 1.7 vs Abelcet), dialysis (RR ¼ 2.4 vs AmBisome; RR ¼ 1.4 vs Abelcet), and death (RR ¼ 2.0 vs AmBisome; RR ¼ 1.1 vs Abelcet) were all increased for patients initiated on AmB-d. Study results suggest that renal function improves and mortality declines when an LFAB is given to HSCT patients as initial therapy rather than as second-line therapy, the current practice. In the last two decades, the number of invasive fungal infections (IFI) in US hospitals has dramatically increased. The most important contributing factor is the growing population of immunocompromised patients. This is partially due to increased access to chemotherapy and hematopoietic stem cell transplant (HSCT), which increase patients' vulnerability to IFI.
Owing to its proven efficacy and broad spectrum of activity, physicians have relied on amphotericin B deoxycholate (AmB-d) as the cornerstone of antifungal therapy for over 40 years. However, it is well known that nephrotoxicity limits the clinical utility of AmB-d and presents a management challenge, especially in patients who have underlying renal dysfunction or who may be receiving concomitant nephrotoxic agents. [1] [2] [3] [4] This is often the case in HSCT recipients, who may be receiving nephrotoxic immunosuppressive, antiviral, or antibiotic regimens in addition to systemic antifungal therapy with AmB-d.
Development of the lipid formulations of amphotericin B (LFABs) represents a major advance in the management of IFI. Three LFABs are currently licensed and marketed in the US: liposomal amphotericin B (AmBisome s , Gilead Sciences, Inc.), amphotericin B lipid complex (Abelcet s , Enzon Pharmaceuticals, Inc.), and amphotericin B colloidal dispersion (Amphotec s , InterMune Pharmaceuticals, Inc.). All the three have been evaluated in clinical studies and are at least as effective as AmB-d, but are associated with less nephrotoxicity. [5] [6] [7] [8] The improved safety profile of LFABs permits administration of higher amphotericin B doses and allows uninterrupted administration of both antifungal and other therapies. As a result, many investigators have pointed out that, were it not for their high acquisition costs, the LFABs would be widely adopted as first-line therapy, and not further debated. 9 Instead, the high acquisition cost limits their prescription in many institutions, and use is often restricted to patients intolerant of, or refractory to, AmB-d.
There is considerable debate over when the LFABs should be used. Data from Wingard (1999) 2 suggest that initiating therapy with AmB-d and waiting until the serum creatinine (SCr) level rises before an LFAB is given often results in high morbidity and mortality and is unlikely to be cost-effective. In that study, HSCT recipients whose SCr level exceeded 2.5 mg/dl after 10 days of amphotericin B therapy had a 490% likelihood of requiring dialysis, and nearly half received dialysis if the SCr level exceeded 2.0 mg/dl. Further, the requirement for dialysis was associated with a three-fold increase in the risk of death. The use of concomitant nephrotoxic agents was also associated with higher mortality. 2 It appears that since HSCT recipients are especially vulnerable to nephrotoxicity, initiating therapy with an LFAB rather than with AmB-d in this patient population would be beneficial.
In this study, we assessed renal function in adult HSCT recipients with proven or probable IFI who were treated with any formulation of amphotericin B. The primary objective was to compare renal function in patients receiving AmB-d or LFABs as initial antifungal therapy. Secondary objectives were to compare clinical response rates and survival.
Patients and methods

Patients
Medical records from eight US centers treating HSCT recipients were reviewed for the period 1995-2000. Patients with evidence of proven or probable IFI, according to the adapted criteria established by the Mycoses Study Group, 10, 11 who had received at least 7 days of amphotericin B therapy with either AmB-d, AmBisome, Abelcet, or Amphotec, were identified. Patients were excluded if they were receiving an investigational antifungal agent in conjunction with amphotericin B therapy, or were enrolled in any prospective antifungal clinical trial. Patients receiving AmB-d are referred to as the AmB-d group. Patients receiving lipid formulations of amphotericin B are referred to as the LFAB group and received either AmBisome, Abelcet, or Amphotec.
Parameters assessed
Demographic factors included age, ethnicity, and gender. Clinical factors included transplant type (allogeneic or autologous), concomitant use of nephrotoxic agents, and proven vs probable mold or yeast infection.
SCr values were extracted from patient charts biweekly (at least 72 h apart), starting at baseline, and collected throughout the course of amphotericin B therapy up to 8 weeks. Baseline was defined as the last SCr value obtained prior to amphotericin B administration. Nephrotoxicity was defined as a doubling of the SCr level compared to baseline and/or an increase in the SCr level to 42.5 mg/dl. The requirement for dialysis was also recorded in each group.
Clinical outcome data included survival and complete and partial response rates, as well as stabilization, or failure of the fungal infection to respond to antifungal therapy, as assessed by the primary physician.
Analysis
A detailed analysis of nephrotoxicity and outcome data was compared between the AmBisome, Abelcet, and AmB-d initial treatment groups. A w 2 test was used to compare categorical values, and a Student's t-test was used to compare continuous variables. The Kruskal-Wallis Rank Sum Test was performed to assess mean percent changes in SCr levels. The Cox Proportional Hazards Model was also used in the nephrotoxicity and outcome analyses. A P-value of p0.05 was considered significant for all statistical tests.
Results
A total of 119 adult HSCT recipients from eight US transplant institutions who were treated with amphotericin B for proven or probable IFI met the eligibility criteria. In total, 51 patients received AmB-d as initial therapy, 18 received AmBisome, 34 received Abelcet, and 16 received Amphotec. A detailed analysis was conducted for patients who received AmB-d, AmBisome, or Abelcet (n ¼ 103).
There were no statistically significant differences among the three treatment groups with respect to baseline demographics and patient information, with the exception of SCr (Table 1) . Baseline SCr was significantly higher in patients who received AmBisome or Abelcet compared to patients who received AmB-d, suggesting that the use of these lipid-based agents was reserved for patients with compromised renal function. At least 50% of patients in each treatment group received at least one concomitant nephrotoxic agent (Table 1) .
Switch from initial therapy
The mean dose prior to dose modifications or conversions was 0.8170.38 mg/kg/day for AmB-d patients, 3.7772.69 mg/kg/day for AmBisome patients, and 4.767 1.42 mg/kg/day for Abelcet patients. Over the 8-week assessment period, 64.7% (33/51) of patients who began treatment with AmB-d were switched to an LFAB ( Figure 1 ). Of these patients, 87.9% (29/33) were switched as a result of amphotericin B-induced nephrotoxicity. In all, 53% (27/51) of patients initiated on AmB-d were switched in the first week of therapy.
A Cox Proportional Hazard Model revealed that patients initiated on AmB-d are 51 times more likely to be switched to an LFAB compared to initial LFAB patients being switched to an alternative LFAB. In contrast, only one patient receiving Abelcet was switched to AmB-d. The reason for the switch, which took place after 11 days of therapy, was not noted. No patients who initially received AmBisome were switched to an alternative amphotericin B formulation ( Figure 1 ).
Renal function
The mean percent change in SCr values from baseline was chosen as the marker of renal function in order to control for baseline differences in SCr among treatment groups.
Renal function was significantly poorer in the first 5 weeks of therapy in patients who received AmB-d compared to patients who received either AmBisome or Abelcet as initial therapy (Figure 2 ). After week 5, the mean percent change in SCr values from baseline remained higher in the AmB-d group compared to the AmBisome or Abelcet groups, but these differences were not statistically significant, possibly due to the small number of patients. As shown in Figure 2 , the majority of patients treated with AmB-d experienced a mean percent change of 4100% in SCr values from baseline over the 8-week follow-up period. Figure 3 shows the mean SCr levels over an 8-week period in the 33 HSCT patients initially treated with AmBd and switched to an LFAB vs those maintained on an LFAB over the same period. Baseline mean SCr was 1.0670.65 and 1.3670.86 mg/dl (P ¼ 0.005) in the AmB-d and LFAB groups, respectively. In patients who received AmB-d, nephrotoxicity was evident within the first week of therapy; mean SCr rose to 2.271.05 mg/dl on or before the switch to an LFAB. In the subsequent 3 weeks following the switch to an LFAB, the mean SCr value steadily declined to levels comparable to those achieved in patients treated with an LFAB for the entire period. It is important to note that of the 33 patients initially switched from AmB-d to LFAB therapy, only eight patients remained in the group by the fourth week of therapy. 
Clinical outcomes
No statistically significant treatment differences were observed with respect to response to treatment for the three groups. A total of 36/103 (35.0%) patients had complete or partial responses to therapy. Treatment failed for 49/103 (47.6%) of patients (Table 3) .
No statistically significant differences were observed among patient groups with respect to survival. A total of 62/103 (60.2%) patients died during the course of the 8-week follow-up period, 34/51 (66.7%) in the AmB-d group, 7/18 (38.9%) in the AmBisome group, and 21/34 (61.8%) in the Abelcet group (Table 3 ). The causes of death in the three treatment groups were consistent with the predisposing conditions of this patient population. Similarly, no significant differences were found among the groups for death due to IFI. IFI was a primary cause of death for 18/62 (29.0%) patients, 10/34 (29.4%) in the AmB-d group, 3/7 (42.9%) in the AmBisome group, and 5/21 (23.8%) in the Abelcet group, (Table 3) 
Discussion
Nephrotoxicity is a major dose-limiting adverse effect of amphotericin B, and its clinical significance has driven the development of LFABs that target sites of fungal infection while sparing the kidneys. Clinical studies have shown that LFABs are just as effective as AmB-d but less nephrotoxic, allowing for sustained antifungal therapy [5] [6] [7] [8] 12, 13 and continuation of concurrent medications. However, the use of LFABs is restricted in many institutions as the acquisition costs are reported to be between 10 and 50 times higher than that of AmB-d. 9 As a result, some institutions reserve LFABs for patients already exhibiting nephrotoxicity from AmB-d therapy, even though the effectiveness of this strategy has not been evaluated in prospective trials.
The current study confirms previous reports of AmB-d nephrotoxicity in a significant proportion of HSCT recipients. The majority of patients treated with AmB-d were switched to an LFAB due to nephrotoxicity, most within the first week of therapy. As expected, baseline SCr was markedly higher in patients selected for and maintained on LFAB treatment throughout the study period compared to those initially receiving AmB-d.
Patients who were initiated on AmB-d exhibited a rapid decline in renal function, and the majority of these patients remained nephrotoxic throughout the follow-up period (Figure 2 ). In contrast, SCr levels remained relatively stable among patients treated initially with an LFAB, and 83% of these patients were able to complete therapy. Due to the high rate of attrition of patients who were switched from AmB-d to an LFAB, we have restricted our conclusions in Figure 3 to the first 3 weeks of therapy following the switch. Table 2 Renal function Although switching patients to an LFAB when signs of nephrotoxicity appear is promoted by some as conventional practice, 14 our results clearly indicate that this strategy is likely not achieving optimal outcomes for HSCT patients.
Patients who were switched from AmB-d to an LFAB experienced more severe renal dysfunction than patients treated initially with an LFAB. This finding was also observed by Prentice et al 8 in a study comparing AmB-d and liposomal amphotericin B in the empiric antifungal treatment of patients with febrile neutropenia. The investigators observed that in a mixed adult/pediatric population with febrile neutropenia, patients treated with liposomal amphotericin B developed nephrotoxicity later, and at a lower incidence, than patients treated with AmB-d. Similarly, a randomized controlled trial comparing AmB-d and liposomal amphotericin B found a significantly higher incidence of nephrotoxicity in patients treated with AmB-d compared to patients treated with liposomal amphotericin B. 6 A more recent study discovered that amphotericin B-induced nephrotoxicity was associated with a 2.7-fold higher risk of death. 15 Using a Cox Proportional Hazard Model, we have also shown that AmB-d increases the risk of death, and that initiating therapy on AmB-d generated a 1.6-fold increase in the risk of developing nephrotoxicity compared to initiating therapy with an LFAB. This is particularly relevant for HSCT patients, who are often on concomitant medications that may also have nephrotoxic side effects. Wingard et al 2 also reported an increased mortality rate associated with toxic renal damage induced by AmB-d use. In particular, dialysis and concomitant nephrotoxic agents may have contributed to the observed increase in the mortality rate. Despite impaired renal function in HSCT patients switched to an LFAB, the period of elevated SCr prior to and during the initial weeks following the switch may be compromising the antifungal or other therapies that these patients may require. 16 Clinicians are forced to focus on managing the nephrotoxicity via dose reductions or discontinuations rather than on treating the fungal infection itself.
Quilitz et al 14 have recently developed an algorithm for the treatment of HSCT patients with proven or probable fungal infections. They suggest that patients at high risk of AmB-d-induced nephrotoxicity or fungal morbidity and mortality be initiated on an LFAB while those at lower risk be initiated on AmB-d therapy. Another report also supports the use of an LFAB as first-line therapy in highrisk patients, 17 while others highlight not only the improved efficacy but also determine that this approach is cost effective. 2, 9, 18 One of the main determinants driving the use of AmB-d as first-line therapy for the treatment of IFIs is the high acquisition cost of LFABs. Recently, a number of studies have examined the pharmacoeconomics of antifungal therapy. 2, 9, 15, [19] [20] [21] They have found that treating renal failure as a result of amphotericin B-induced nephrotoxicity is more expensive than initiating and maintaining patients on an LFAB. Most importantly, this strategy has been associated with a reduction in overall morbidity and mortality. 15, 20, 22 In a retrospective chart review study of 239 immunocompromised patients receiving AmB-d for suspected or proven aspergillosis, Wingard et al 2 suggested that clinicians employ an alternative strategy of using the LFABs early, when the outcome following the use of AmB-d is expected to be poor, or when costly interventions such as hemodialysis or prolonged hospital stays are likely. Indeed, our data suggest that initiating first-line therapy with an LFAB, even in those patients with no overt renal dysfunction, may result in optimal antifungal therapy by avoiding the diversion of care toward the management of nephrotoxicity and related issues.
It is well established that the LFABs are less nephrotoxic than AmB-d 6, 8, 23, 24 and, furthermore, there is growing evidence that the various LFABs differ in their propensity to induce nephrotoxicity. A study by Wingard et al 25 showed that treatment with AmBisome resulted in a significantly lower incidence of nephrotoxicity compared to treatment with Abelcet. This difference may be attributed to the different pharmacokinetic properties of these two formulations, 26 allowing delivery of AmBisome at much higher doses while maintaining effectiveness and tolerability. 27 In our study, we collected and reported on efficacy data in order to ensure that lower rates of nephrotoxicity were achieved without diminishing efficacy. No statistically significant differences were found between the three treatment groups with respect to response rates to therapy or survival. However, the limited sample size and the retrospective design of this study did not permit conclusions to be drawn about the efficacy of AmB-d compared to the LFABs. Further, we could not differentiate the incidence of nephrotoxicity resulting from administration of AmBisome or Abelcet. However, a Cox Proportional Hazards Model did reveal that AmB-d increases the risk of dialysis by 2.4 times when compared to AmBisome and 1.4 times when compared to Abelcet.
In conclusion, based on this retrospective chart review, nephrotoxicity resulting from AmB-d therapy occurs frequently in HSCT recipients, and results in the majority of patients being switched to an LFAB after a relatively short period of time. Amphotericin B is significantly better tolerated when an LFAB is given as initial therapy rather than as second-line therapy, according to current practice.
